KIFC1 and cancer: In contrast the specificity of the dependency on the KIFC1 kinesin to centrosome-amplified cancer cells offers the possibility of a potentially druggable malignant cell-specific target and a mechanism-based patient selection biomarker of centrosome abnormality that can be applied to routinely collected formalin-fixed tumors.